



05-03-05

1648
CFW

Attorney Docket No. 1907.03

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Wettstein et al.)

Application No.: 09/972,035)

Filed: October 4, 2001)

For: TSG101-GAGP6 INTERACTION
AND USE THEREOF)

Group Art Unit: 1648

Examiner: M. Hill

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 600557705 US

Date of Deposit: May 2, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rachael M. Harris
Rachael M. Harris

5/2/2005
Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(c)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a list of documents on form PTO/SB/08A together with copies of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56.


To the best of the undersigned person's knowledge, this Supplemental Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(c), before either (a) the mailing date of a Final Office Action, (b) a Notice of Allowance, or (c) any other action that otherwise closes prosecution, whichever is earlier.

In accordance with the requirements of 37 CFR § 1.97(c)(1), the following Certification as specified in 37 CFR § 1.97(e) is made:

Each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

It is believed that neither an extension of time, nor payment of any other fee is required in connection with this communication. However, if an extension of time, a corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. **50-1627**.


Respectfully submitted,



Herbert L. Ley III, Ph.D.
Registration No. 53,215

Intellectual Property Department
Myriad Genetics, Inc.
(Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-883-3871

Date: May 2, 2005



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/972,035
		Filing Date	October 4, 2001
		First Named Inventor	Daniel Albert Wettstein
		Art Unit	1648
		Examiner Name	M. Hill
Sheet 1 of 1	Attorney Docket Number	1907.03	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Supplementary European Search Report dated February 11, 2005 (2 pages).	
		Sun et al., "Tumor Susceptibility Gene 101 Protein Represses Androgen Receptor Transactivation and Interacts with p300", <i>Cancer</i> , August 15, 1999, 86(4):689-696.	
		VerPlank et al., "Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55 ^{Gag} ", <i>PNAS</i> , July 3, 2001, 98(14):7724-7729.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.